GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (FRA:IM8N) » Definitions » Margin of Safety % (DCF FCF Based)

Insmed (FRA:IM8N) Margin of Safety % (DCF FCF Based) : N/A (As of Dec. 12, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Insmed Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Insmed's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.


Competitive Comparison of Insmed's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Insmed's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insmed's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Insmed's Margin of Safety % (DCF FCF Based) falls into.



Insmed Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Insmed's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.


Insmed Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (FRA:IM8N) » Definitions » Margin of Safety % (DCF FCF Based)
Traded in Other Exchanges
Address
700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.

Insmed Headlines

No Headlines